Does CyberKnife improve dose distribution versus IMRT and VMAT on a linear accelerator in low-risk prostate cancer?

CyberKnife, IMRT and VMAT in low risk prostate cancer.

Abstract

Background. Hypofractionated stereotactic body radiation therapy (SBRT) for prostate cancer (PCa) can be delivered with the robot-assisted CyberKnife (CK) system or on a linear accelerator using dynamic IMRT or VMAT. This retrospective study was performed to determine whether CK offers better dose distribution than IMRT and/or VMAT.

Materials and methods. Treatment plans for three techniques were prepared using the same treatment parameters (36.35 Gy, 7.25 Gy/fr). We evaluated target coverage, conformity index (CI), homogeneity index (HI), gamma index (GI), and OAR constraints.  

Results. The mean PTV dose for CK (39.58 Gy) was significantly greater than VMAT or IMRT (both 36.25 Gy). However, CK resulted in a wider dose range (31.48 to 45.89 Gy) vs VMAT and IMRT (34.6 - 38.76 Gy). The mean dose to the rectum (V36Gy, mm3) was significantly lower (p<0.001) in the CK plans (219.78 vs. 519.59 and 422.62, respectively). The mean bladder dose (V37Gy, mm3) was significantly greater for CK (3256 vs. 1090.75 for VMAT and 4.5 for IMRT (p<0.001). CK yielded significantly better CI (1.07 vs. 1.17 and 1.25 for VMAT and IMRT, respectively; p<0.01) and HI values (1.27 vs. 1.07 and 1.04; p<0.01). GI values for the δd=3mm, δ%=3% criteria were 99.86 (VMAT), 99.07 (IMRT) and 99.99 (CK). For δd=2mm, δ%=2%, the corresponding values were 98.3, 93.35, and 97.12, respectively.

Conclusions. For most variables, CK was superior to both VMAT and IMRT. However, dynamic IMRT techniques, especially VMAT, do not differ significantly from CK plans and are therefore acceptable alternatives to CyberKnife.